Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

NCT07150767 is registered in ClinicalTrials.gov with Beijing Bio-Targeting Therapeutics Technology Co., Ltd as lead sponsor.

NCT NCT07150767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07150767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer
Lead sponsor
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase
Phase 1
Overall status
Withdrawn
Start date
March 26, 2025
Completion date
March 26, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced breast cancer (labc)